Author: admin

Most cancer diagnostics only scratch the surface of the genome, potentially missing key alterations that could transform patient outcomes. A new platform that combines whole-genome sequencing with advanced bioinformatics and machine learning delivers clinically actionable insights that go beyond traditional panel tests.Jehee SuhChief Executive OfficerInocrasIn this Innovation Spotlight, Jehee Suh, the chief executive officer of Inocras, highlights how the company’s technology is defining a new standard in precision oncology, from identifying rare genomic variants to supporting the optimization of patient management. Additionally, he introduces their 100,000-patient genome program, which aims to build one of the largest cancer-genome datasets in the…

Novo Nordisk is doubling down on obesity and diabetes. Speaking with Inside Precision Medicine at the 2026 J.P. Morgan Healthcare Conference, head of research Jacob Petersen said recent internal changes have pushed the company to go deeper—and broader—across both diseases. The aim, Petersen emphasized, is not just incremental weight loss but better cardiovascular, renal, and metabolic outcomes, fewer gastrointestinal side effects, and less frequent dosing. That means Novo Nordisk is expanding beyond injectables into oral options like the newly launched Wegovy pill, while building next-generation combinations spanning incretins GLP-1 (Glucagon-Like Peptide-1) and GIP (Glucose-Dependent Insulinotropic Polypeptide) and amylins, glucagon, and…

The question of what came first, the chicken or the egg, is perhaps the most famous paradox in human history. For centuries, it has served as a linguistic shorthand for circular reasoning, a centerpiece for deep philosophical debate, and a favorite topic for late-night scientific deep dives. Depending on who you ask—an evolutionary biologist, a theologian, a philosopher, or a comedian—the answer changes dramatically. At its core, the inquiry of what came first chicken or the egg, challenges our understanding of cause and effect. If a chicken must come from an egg, but an egg must be laid by a…

Scientists at the Icahn School of Medicine at Mount Sinai have developed an experimental immunotherapy that takes an unconventional approach to metastatic cancer. Rather than targeting cancer cells directly, the new strategy—which they suggest is akin to that of the Trojan horse—targets the tumor-associated macrophages (TAMs) that protect the tumor and keep the tumor microenvironment (TME) immunosuppressed. The team developed IL-12-producing CAR T cells that directly target and disarm these tumor-associated macrophages, opening the tumor’s gates for the immune system to then enter and wipe out the cancer cells. The researchers demonstrated that the CAR T cell therapy increased survival…

In the past year, more than half of the leaders of the Institutes and Centers (IC) at the National Institutes of Health (NIH), as well as many other career government scientists across the agency, have left as part of President Trump’s agenda to reform and reduce the size of the federal government. While fresh perspectives and new vision can be positive, as a former NIH leader and biomedical research advocate, I worry that this rapid and substantial loss of institutional knowledge will be bad for those who NIH ultimately serves: patients and the American people.Change Is Good, Loss of Expertise…

Credit: jro-grafik/Fotolia Mendra has come out of stealth mode with an $82 million Series A fundraising round, which it plans to use to bring rare disease therapeutics to as many people as possible with the help of artificial intelligence (AI). The biotech launched in stealth mode in San Francisco in 2025 and is drawing on the expertise of its CEO Joshua Grass and its commercial lead Jeff Ajer who helped build and launch BioMarin’s rare-disease portfolio. Grass also ran Escient Pharmaceuticals from 2022 until its acquisition by Incyte in 2024, giving him recent experience taking a biotech from growth stage…

Researchers from Singapore’s A*STAR Institute of Molecular and Cell Biology (A*STAR IMCB) report that they have identified why certain lung cancer cells become highly resistant to treatment after developing mutations in the EGFR (epidermal growth factor receptor) gene. In a study “A genome-wide genetic screen reveals the P2Y2-integrin axis as a stabilizer of EGFR mutants in non–small cell lung cancer (NSCLC)” published in Science Advances, the team revealed a previously unknown survival mechanism and demonstrated that disrupting it can shrink tumors in laboratory models. Many lung cancer cases are driven by mutations in the EGFR gene. In Southeast Asia, these…

Credit: luismmolina / iStock / Getty Images Plus With a single drop of blood, orphan non-coding RNA (oncRNA) expression patterns could be used to identify cancer subtypes and monitor disease progression in real time. In a study published today in Cell, scientists systematically mapped oncRNAs across 32 major cancer types, investigated their role in disease progression and metastasis, and validated their potential as prognostic biomarkers.  “We think oncRNAs represent a new class of cancer-emergent molecules that function as both drivers and biomarkers,” write the authors of the study, led by Hani Goodarzi, PhD, associate professor at the University of California,…

Imagine going to the hospital for a bacterial ear infection and hearing your doctor say, “We’re out of options.” It may sound dramatic, but antibiotic resistance is pushing that scenario closer to becoming reality for an increasing number of people. In 2016, a woman from Nevada died from a bacterial infection that was resistant to all 26 antibiotics that were available in the United States at that time.The US alone sees more than 2.8 million antibiotic-resistant illnesses each year. Globally, antimicrobial resistance is linked to nearly 5 million deaths annually.1Bacteria naturally evolve in ways that can make the drugs meant…

Credit: chaikom/Getty Images Boston University researchers say that a measure derived from electroencephalography (EEG) combined with transcranial magnetic stimulation (TMS) can distinguish people with Alzheimer’s disease (AD) from healthy older adults by detecting reduced brain response complexity. The study, published in the journal Neuroscience of Consciousness, that a measure that has been used to assess coma and minimally conscious states, called perturbation complexity index–state transitions (PCI-ST), is lower in individuals with AD, suggesting altered cortical network function related to impaired conscious cognitive processes. If further validated, the use of TMS-EEG to measured PCI-ST could become a quantitative biomarker that could…